Australia markets open in 26 minutes

ARCA biopharma, Inc. (ABIO)

NasdaqCM - NasdaqCM Delayed price. Currency in USD
Add to watchlist
3.3100-0.1800 (-5.16%)
At close: 04:00PM EDT
3.3100 0.00 (0.00%)
After hours: 07:23PM EDT
Full screen
Trade prices are not sourced from all markets
Previous close3.4900
Open3.4900
Bid3.2300 x 100
Ask3.3800 x 100
Day's range3.2200 - 3.6500
52-week range1.5600 - 4.4900
Volume141,276
Avg. volume114,054
Market cap48.019M
Beta (5Y monthly)0.89
PE ratio (TTM)N/A
EPS (TTM)-0.4200
Earnings date19 July 2024 - 23 July 2024
Forward dividend & yieldN/A (N/A)
Ex-dividend dateN/A
1y target estN/A
  • Insider Monkey

    Why Are Hedge Funds Shorting ARCA Biopharma, Inc. (ABIO)?

    We recently compiled a list of What Is Short Selling In Stock Market? 15 Stocks Hedge Funds are Shorting. In this article, we are going to take a look at where ARCA Biopharma, Inc. (NASDAQ:ABIO) stands against the other stocks hedge funds are shorting. Short selling, also known as shorting or going short, is a […]

  • GlobeNewswire

    ARCA biopharma Announces First Quarter 2024 Financial Results and Provides Corporate Update

    ARCA biopharma and Oruka Therapeutics announce Merger AgreementARCA biopharma appoints Thomas Keuer as President WESTMINSTER, Colo., April 25, 2024 (GLOBE NEWSWIRE) -- ARCA biopharma, Inc. (Nasdaq: ABIO), (the “Company”) a biopharmaceutical company applying a precision medicine approach to developing genetically targeted therapies for cardiovascular diseases, today reported first quarter 2024 financial results and provided a corporate update. In April 2022, ARCA established a Special Committee o

  • GlobeNewswire

    ARCA biopharma and Oruka Therapeutics Announce Merger Agreement

    Merger to create a company focused on advancing Oruka’s portfolio of novel biologics that aim to redefine the standard of care for patients with chronic skin diseases Oruka, the third company founded based on assets generated by Paragon Therapeutics, expects to advance ORKA-001 and ORKA-002, potentially best-in-class antibodies targeting IL-23p19 and IL-17A/F, respectively, into clinical trials in 2025 Pre-closing private financing of approximately $275 million anticipated to fund operations thr